| Company Announcements: (reported by the Company) |
No items found
|
| Elevator Pitch: | Aspecthera is a pre-clinical stage pharmaceutical company developing a non-invasive eye-drop therapy for diabetic retinopathy, a leading cause of vision loss on a global scale. The company was spun-out of the University of Tasmania in 2024 with support from UTAS InVent (Innovation Ventures). Our patient-centric candidate eye-drop therapy is highly differentiated from the current standard-of-care, which involves a burdensome intravitreal (eye injection) treatment paradigm, and also shows promise for early-stage disease intervention filling a large unmet medical need.  |
| Category: | Health & biotech |
| URL: | https://www.linkedin.com/company/aspecthera |
| Operational Status: | Active |
| ASX Listing Code (if applicable): | |
| Year of Commencement: | 2024 |
| Address: | SANDY BAY TAS 7005 |
| State: | Tasmania |
| Overseas Operations: | No |
| Twitter: | |
| Facebook: | |
| Linkedin: | https://www.linkedin.com/company/aspecthera/ |
| Founders: |
No items found
|
| Awards won: | |
